pakt 473 smad2 raised  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc pakt 473 smad2 raised
    Smad protein levels for human aortic endothelial cells (HAEC) exposed to 20 h of 2 and 10 dyn/cm2 average shear stresses at 80 ± 5 mmHg and exemplary Western blot lanes. Each plot point represents the average value for the indicated number of samples. Western blot quantification was performed on raw image data and normalized to total kinase levels for each lane. A: cytosolic (n = 10) and nuclear (n = 3) L-psmad2 profiles. B: Western blot lanes showing COOH-terminal phosphorylated <t>Smad2</t> levels under flow for 20 h or treated with 1 ng/ml transforming growth factor (TGF)-β1 for 1 h. *P < 0.05.
    Pakt 473 Smad2 Raised, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pakt 473 smad2 raised/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pakt 473 smad2 raised - by Bioz Stars, 2023-03
    96/100 stars

    Images

    1) Product Images from "Flow-dependent Smad2 phosphorylation and TGIF nuclear localization in human aortic endothelial cells"

    Article Title: Flow-dependent Smad2 phosphorylation and TGIF nuclear localization in human aortic endothelial cells

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    doi: 10.1152/ajpheart.00668.2010

    Smad protein levels for human aortic endothelial cells (HAEC) exposed to 20 h of 2 and 10 dyn/cm2 average shear stresses at 80 ± 5 mmHg and exemplary Western blot lanes. Each plot point represents the average value for the indicated number of samples. Western blot quantification was performed on raw image data and normalized to total kinase levels for each lane. A: cytosolic (n = 10) and nuclear (n = 3) L-psmad2 profiles. B: Western blot lanes showing COOH-terminal phosphorylated Smad2 levels under flow for 20 h or treated with 1 ng/ml transforming growth factor (TGF)-β1 for 1 h. *P < 0.05.
    Figure Legend Snippet: Smad protein levels for human aortic endothelial cells (HAEC) exposed to 20 h of 2 and 10 dyn/cm2 average shear stresses at 80 ± 5 mmHg and exemplary Western blot lanes. Each plot point represents the average value for the indicated number of samples. Western blot quantification was performed on raw image data and normalized to total kinase levels for each lane. A: cytosolic (n = 10) and nuclear (n = 3) L-psmad2 profiles. B: Western blot lanes showing COOH-terminal phosphorylated Smad2 levels under flow for 20 h or treated with 1 ng/ml transforming growth factor (TGF)-β1 for 1 h. *P < 0.05.

    Techniques Used: Western Blot

    MAPK and Smad2 activity with chemical inhibitors of the ERK and phosphatidylinositol 3-kinase (PI3K) pathways at 20 h of 10 dyn/cm2, average shear stress at 80 ± 5 mmHg, and exemplary Western blot lanes. Plot points and blot quantification was performed as in Fig. 1. A: ERK phosphorylation in the presence of 10 μmol/l PD98059. For 10 dyn/cm2 and 10 dyn/cm2 + PD98059: n = 3. B: L-psmad2 levels in the presence of 10 μmol/l PD98059. For 10 dyn/cm2, n = 4, and for 10 dyn/cm2 + PD98059: n = 3. C: L-psmad2 levels in the presence of 40 μmol/l LY294002 and 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, for 10 dyn/cm2 + LY294002, n = 2, and for 10 dyn/cm2 + PI-103, n = 3. D: JNK phosphorylation in the presence of 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, and for 10 dyn/cm2 + PI-103, n = 3. *P < 0.05; **P < 0.01; ‡P < 0.0001.
    Figure Legend Snippet: MAPK and Smad2 activity with chemical inhibitors of the ERK and phosphatidylinositol 3-kinase (PI3K) pathways at 20 h of 10 dyn/cm2, average shear stress at 80 ± 5 mmHg, and exemplary Western blot lanes. Plot points and blot quantification was performed as in Fig. 1. A: ERK phosphorylation in the presence of 10 μmol/l PD98059. For 10 dyn/cm2 and 10 dyn/cm2 + PD98059: n = 3. B: L-psmad2 levels in the presence of 10 μmol/l PD98059. For 10 dyn/cm2, n = 4, and for 10 dyn/cm2 + PD98059: n = 3. C: L-psmad2 levels in the presence of 40 μmol/l LY294002 and 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, for 10 dyn/cm2 + LY294002, n = 2, and for 10 dyn/cm2 + PI-103, n = 3. D: JNK phosphorylation in the presence of 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, and for 10 dyn/cm2 + PI-103, n = 3. *P < 0.05; **P < 0.01; ‡P < 0.0001.

    Techniques Used: Activity Assay, Western Blot

    Duolink Assay results for static and flow exposed HAEC. Protein associations determined by Cy3 channel confocal microscopy signal. Nuclei are counterstained with 4',6-diamidino-2-phenylindole (DAPI). A: total Akt and Smad2 association, n = 2. B: Smad2 and pAkt473 association. Enhanced cytoplasmic staining is evident with both sets of antibodies, indicating that colocalization of the proteins was occurring preferentially under flow stimulation.
    Figure Legend Snippet: Duolink Assay results for static and flow exposed HAEC. Protein associations determined by Cy3 channel confocal microscopy signal. Nuclei are counterstained with 4',6-diamidino-2-phenylindole (DAPI). A: total Akt and Smad2 association, n = 2. B: Smad2 and pAkt473 association. Enhanced cytoplasmic staining is evident with both sets of antibodies, indicating that colocalization of the proteins was occurring preferentially under flow stimulation.

    Techniques Used: Confocal Microscopy, Staining

    smad2 3 pakt  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc smad2 3 pakt
    A., and <t>Smad2</t> and Smad3 mRNA B. ; and TMEPAI mRNA C. in human normal mammary epithelial cells (HMEC) and various triple negative breast cancer cell lines (MDA-MB-231, BT20, HCC1937, MDA-MB-157, Hs578T) along with TMEPAI knockdown MDA-MB-231 cells (231-TMKD/TMKD).
    Smad2 3 Pakt, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/smad2 3 pakt/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    smad2 3 pakt - by Bioz Stars, 2023-03
    86/100 stars

    Images

    1) Product Images from "Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer"

    Article Title: Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

    Journal: Genes & Cancer

    doi: 10.18632/genesandcancer.194

    A., and Smad2 and Smad3 mRNA B. ; and TMEPAI mRNA C. in human normal mammary epithelial cells (HMEC) and various triple negative breast cancer cell lines (MDA-MB-231, BT20, HCC1937, MDA-MB-157, Hs578T) along with TMEPAI knockdown MDA-MB-231 cells (231-TMKD/TMKD).
    Figure Legend Snippet: A., and Smad2 and Smad3 mRNA B. ; and TMEPAI mRNA C. in human normal mammary epithelial cells (HMEC) and various triple negative breast cancer cell lines (MDA-MB-231, BT20, HCC1937, MDA-MB-157, Hs578T) along with TMEPAI knockdown MDA-MB-231 cells (231-TMKD/TMKD).

    Techniques Used:

    A. Relative levels of Smad2, Smad3, TMEPAI and GAPDH in MDA-MB-231 cells expressing control shRNA, Smad2 shRNA and Smad3 shRNA. B.-E. Growth curves of MDA-MB-231 cells expressing control shRNA (B), Smad2 shRNA (C), Smad3 shRNA (D) and TMEPAI shRNA (E) in the absence or presence of TGF-β (2 ng/ml).
    Figure Legend Snippet: A. Relative levels of Smad2, Smad3, TMEPAI and GAPDH in MDA-MB-231 cells expressing control shRNA, Smad2 shRNA and Smad3 shRNA. B.-E. Growth curves of MDA-MB-231 cells expressing control shRNA (B), Smad2 shRNA (C), Smad3 shRNA (D) and TMEPAI shRNA (E) in the absence or presence of TGF-β (2 ng/ml).

    Techniques Used: Expressing, shRNA

    A. Relative expression of phospho Smad2/3, Total Smad2/3 and TMEPAI in MDA-MB-231 cells expressing Con shRNA, Smad2 shRNA and Smad3 shRNA in the absence or presence of TGF-β (2 ng/ml), B. Relative levels of TMEPAI mRNAs in human mammary epithelial cells (HME) and MDA-MB-231 cells that are expressing Con shRNA, TMEPAI shRNA (TMKD), Smad2 shRNA (Smad2KD) or Smad3 shRNA (Smad3KD) in the absence or presence of TGF-β (2 ng/ml), C. 12XCAGA-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA, Smad2 shRNA, Smad3 shRNA both in the absence or presence of TGF-β (2 ng/ml). D. 3XARE-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA, Smad2 shRNA, Smad3 shRNA both in the absence or presence of TGF-β (2 ng/ml). E. 12xCAGA-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA (231_CON) and TMEPAI shRNA (231_TMKD) in the absence or presence of TGF-β (2 ng/ml). F. 3XARE-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA (231_CON) and TMEPAI shRNA (231_TMKD) in the absence or presence of TGF-β (2 ng/ml). G. Schematic representation of three different size TMEPAI promoters tagged with luciferase reporter (−2251-Luc, −973-Luc, −301-Luc) and corresponding luciferase reporter activities in MDA-MB-231 cells in the absence or presence of TGF-β (2 ng/ml). H. TMEPAI promoter activity in MDA-MB-231 cells expressing con shRNA, Smad2 shRNA, and Smad3 shRNA in the absence or presence of TGF-β (2 ng/ml) using 2251 bp TMEPAI promoter (−2251-Luc).
    Figure Legend Snippet: A. Relative expression of phospho Smad2/3, Total Smad2/3 and TMEPAI in MDA-MB-231 cells expressing Con shRNA, Smad2 shRNA and Smad3 shRNA in the absence or presence of TGF-β (2 ng/ml), B. Relative levels of TMEPAI mRNAs in human mammary epithelial cells (HME) and MDA-MB-231 cells that are expressing Con shRNA, TMEPAI shRNA (TMKD), Smad2 shRNA (Smad2KD) or Smad3 shRNA (Smad3KD) in the absence or presence of TGF-β (2 ng/ml), C. 12XCAGA-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA, Smad2 shRNA, Smad3 shRNA both in the absence or presence of TGF-β (2 ng/ml). D. 3XARE-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA, Smad2 shRNA, Smad3 shRNA both in the absence or presence of TGF-β (2 ng/ml). E. 12xCAGA-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA (231_CON) and TMEPAI shRNA (231_TMKD) in the absence or presence of TGF-β (2 ng/ml). F. 3XARE-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA (231_CON) and TMEPAI shRNA (231_TMKD) in the absence or presence of TGF-β (2 ng/ml). G. Schematic representation of three different size TMEPAI promoters tagged with luciferase reporter (−2251-Luc, −973-Luc, −301-Luc) and corresponding luciferase reporter activities in MDA-MB-231 cells in the absence or presence of TGF-β (2 ng/ml). H. TMEPAI promoter activity in MDA-MB-231 cells expressing con shRNA, Smad2 shRNA, and Smad3 shRNA in the absence or presence of TGF-β (2 ng/ml) using 2251 bp TMEPAI promoter (−2251-Luc).

    Techniques Used: Expressing, shRNA, Activity Assay, Luciferase

    A. Growth curves of MDA-MB-231 cells expressing control shRNA (CON shRNA), Smad2 shRNA, Smad3 shRNA or Smad3shRNA along with human TMEPAI cDNA (Smad3 shRNA+hTM) in the absence or presence of TGF-β (2 ng/ml). B. Relative expression of phosphorylated Akt (pAkt), Smad2, Smad3, Snail, Slug, PTEN, p27 and TMEPAI in MDA-MB-231 cells expressing Con shRNA (CON), Smad2 shRNA (S2KD), Smad3 shRNA (S3KD) and Smad3 shRNA along with human TMEPAI cDNA (S3KD+hTM) in the absence or presence of TGF-β (2 ng/ml). Phase contrast images of toluidine blue stained transit well invasion assay (C) and relative invasion index (D) of MDA-MB-231 cells expressing control shRNA (CON shRNA), Smad2 shRNA, Smad3 shRNA and Smad3shRNA along with human TMEPAI cDNA in the absence or presence of TGF-β (2 ng/ml).
    Figure Legend Snippet: A. Growth curves of MDA-MB-231 cells expressing control shRNA (CON shRNA), Smad2 shRNA, Smad3 shRNA or Smad3shRNA along with human TMEPAI cDNA (Smad3 shRNA+hTM) in the absence or presence of TGF-β (2 ng/ml). B. Relative expression of phosphorylated Akt (pAkt), Smad2, Smad3, Snail, Slug, PTEN, p27 and TMEPAI in MDA-MB-231 cells expressing Con shRNA (CON), Smad2 shRNA (S2KD), Smad3 shRNA (S3KD) and Smad3 shRNA along with human TMEPAI cDNA (S3KD+hTM) in the absence or presence of TGF-β (2 ng/ml). Phase contrast images of toluidine blue stained transit well invasion assay (C) and relative invasion index (D) of MDA-MB-231 cells expressing control shRNA (CON shRNA), Smad2 shRNA, Smad3 shRNA and Smad3shRNA along with human TMEPAI cDNA in the absence or presence of TGF-β (2 ng/ml).

    Techniques Used: Expressing, shRNA, Staining, Invasion Assay

    Relative mRNA expression of Smad2 A. , Smad3 B. , TMEPAI C. , Snai1 D. , Slug E. in MDA-MB-231 (231) cells that are expressing control, TMEPAI (TMKD), Smad2 (Smad2KD) and Smad3 (Smad3KD) shRNAs in the absence or presence of TGF-β (2 ng/ml) relative to normal human mammary epithelial cells (HMEC).
    Figure Legend Snippet: Relative mRNA expression of Smad2 A. , Smad3 B. , TMEPAI C. , Snai1 D. , Slug E. in MDA-MB-231 (231) cells that are expressing control, TMEPAI (TMKD), Smad2 (Smad2KD) and Smad3 (Smad3KD) shRNAs in the absence or presence of TGF-β (2 ng/ml) relative to normal human mammary epithelial cells (HMEC).

    Techniques Used: Expressing

    A. Relative expression of Smad2, Smad3 and TMEPAI in Control (HCC), Smad2 knockdown (S2KD) and Smad3 knockdown (S3KD) HCC1937 TNBC cells. B. Growth of control HCC1937 (HCC) in the presence and absence of TGF-β. C. Growth of Smad2 knockdown HCC1937 (S2KD) in the presence and absence of TGF-β. D. Growth of Smad3 knockdown HCC1937 (S3KD) in the presence and absence of TGF-β. E. Relative expressions of E-Cad, Snail and Slug in control (CON) and TMEPAI knockdown (TMKD) HCC1937 cells. F. Relative expressions of E-Cad and Vimentin in control (CON), Smad2 knockdown (S2KD) and Smad3 knockdown (S3KD) HCC1937 cells.
    Figure Legend Snippet: A. Relative expression of Smad2, Smad3 and TMEPAI in Control (HCC), Smad2 knockdown (S2KD) and Smad3 knockdown (S3KD) HCC1937 TNBC cells. B. Growth of control HCC1937 (HCC) in the presence and absence of TGF-β. C. Growth of Smad2 knockdown HCC1937 (S2KD) in the presence and absence of TGF-β. D. Growth of Smad3 knockdown HCC1937 (S3KD) in the presence and absence of TGF-β. E. Relative expressions of E-Cad, Snail and Slug in control (CON) and TMEPAI knockdown (TMKD) HCC1937 cells. F. Relative expressions of E-Cad and Vimentin in control (CON), Smad2 knockdown (S2KD) and Smad3 knockdown (S3KD) HCC1937 cells.

    Techniques Used: Expressing

    Kaplan Meier curves for overall survival of triple negative breast cancer patients in relation to expression of TMEPAI/PMEPA1 (A), Smad2 (B), Smad3 (C) or Smad4 (D) mRNA using a publicly accessible database (GSE58812). E. Western blots of TMEPAI and total Smad2/3 proteins in primary tumors from human breast cancer patients (BC1- BC5) and corresponding normal/benign (N1-N4) samples relative to MDA-MB-231 cells (231).
    Figure Legend Snippet: Kaplan Meier curves for overall survival of triple negative breast cancer patients in relation to expression of TMEPAI/PMEPA1 (A), Smad2 (B), Smad3 (C) or Smad4 (D) mRNA using a publicly accessible database (GSE58812). E. Western blots of TMEPAI and total Smad2/3 proteins in primary tumors from human breast cancer patients (BC1- BC5) and corresponding normal/benign (N1-N4) samples relative to MDA-MB-231 cells (231).

    Techniques Used: Expressing, Western Blot

    The data demonstrate that the consequences of switch from Smad2 to Smad3 signaling pathway results in converting TGF-β from tumor suppressor to pro-oncogene as cells acquire increasing malignant properties through Smad3 mediated TMEPAI expression.
    Figure Legend Snippet: The data demonstrate that the consequences of switch from Smad2 to Smad3 signaling pathway results in converting TGF-β from tumor suppressor to pro-oncogene as cells acquire increasing malignant properties through Smad3 mediated TMEPAI expression.

    Techniques Used: Expressing

    pakt 473 smad2 raised  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc pakt 473 smad2 raised
    Smad protein levels for human aortic endothelial cells (HAEC) exposed to 20 h of 2 and 10 dyn/cm2 average shear stresses at 80 ± 5 mmHg and exemplary Western blot lanes. Each plot point represents the average value for the indicated number of samples. Western blot quantification was performed on raw image data and normalized to total kinase levels for each lane. A: cytosolic (n = 10) and nuclear (n = 3) L-psmad2 profiles. B: Western blot lanes showing COOH-terminal phosphorylated <t>Smad2</t> levels under flow for 20 h or treated with 1 ng/ml transforming growth factor (TGF)-β1 for 1 h. *P < 0.05.
    Pakt 473 Smad2 Raised, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pakt 473 smad2 raised/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pakt 473 smad2 raised - by Bioz Stars, 2023-03
    96/100 stars

    Images

    1) Product Images from "Flow-dependent Smad2 phosphorylation and TGIF nuclear localization in human aortic endothelial cells"

    Article Title: Flow-dependent Smad2 phosphorylation and TGIF nuclear localization in human aortic endothelial cells

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    doi: 10.1152/ajpheart.00668.2010

    Smad protein levels for human aortic endothelial cells (HAEC) exposed to 20 h of 2 and 10 dyn/cm2 average shear stresses at 80 ± 5 mmHg and exemplary Western blot lanes. Each plot point represents the average value for the indicated number of samples. Western blot quantification was performed on raw image data and normalized to total kinase levels for each lane. A: cytosolic (n = 10) and nuclear (n = 3) L-psmad2 profiles. B: Western blot lanes showing COOH-terminal phosphorylated Smad2 levels under flow for 20 h or treated with 1 ng/ml transforming growth factor (TGF)-β1 for 1 h. *P < 0.05.
    Figure Legend Snippet: Smad protein levels for human aortic endothelial cells (HAEC) exposed to 20 h of 2 and 10 dyn/cm2 average shear stresses at 80 ± 5 mmHg and exemplary Western blot lanes. Each plot point represents the average value for the indicated number of samples. Western blot quantification was performed on raw image data and normalized to total kinase levels for each lane. A: cytosolic (n = 10) and nuclear (n = 3) L-psmad2 profiles. B: Western blot lanes showing COOH-terminal phosphorylated Smad2 levels under flow for 20 h or treated with 1 ng/ml transforming growth factor (TGF)-β1 for 1 h. *P < 0.05.

    Techniques Used: Western Blot

    MAPK and Smad2 activity with chemical inhibitors of the ERK and phosphatidylinositol 3-kinase (PI3K) pathways at 20 h of 10 dyn/cm2, average shear stress at 80 ± 5 mmHg, and exemplary Western blot lanes. Plot points and blot quantification was performed as in Fig. 1. A: ERK phosphorylation in the presence of 10 μmol/l PD98059. For 10 dyn/cm2 and 10 dyn/cm2 + PD98059: n = 3. B: L-psmad2 levels in the presence of 10 μmol/l PD98059. For 10 dyn/cm2, n = 4, and for 10 dyn/cm2 + PD98059: n = 3. C: L-psmad2 levels in the presence of 40 μmol/l LY294002 and 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, for 10 dyn/cm2 + LY294002, n = 2, and for 10 dyn/cm2 + PI-103, n = 3. D: JNK phosphorylation in the presence of 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, and for 10 dyn/cm2 + PI-103, n = 3. *P < 0.05; **P < 0.01; ‡P < 0.0001.
    Figure Legend Snippet: MAPK and Smad2 activity with chemical inhibitors of the ERK and phosphatidylinositol 3-kinase (PI3K) pathways at 20 h of 10 dyn/cm2, average shear stress at 80 ± 5 mmHg, and exemplary Western blot lanes. Plot points and blot quantification was performed as in Fig. 1. A: ERK phosphorylation in the presence of 10 μmol/l PD98059. For 10 dyn/cm2 and 10 dyn/cm2 + PD98059: n = 3. B: L-psmad2 levels in the presence of 10 μmol/l PD98059. For 10 dyn/cm2, n = 4, and for 10 dyn/cm2 + PD98059: n = 3. C: L-psmad2 levels in the presence of 40 μmol/l LY294002 and 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, for 10 dyn/cm2 + LY294002, n = 2, and for 10 dyn/cm2 + PI-103, n = 3. D: JNK phosphorylation in the presence of 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, and for 10 dyn/cm2 + PI-103, n = 3. *P < 0.05; **P < 0.01; ‡P < 0.0001.

    Techniques Used: Activity Assay, Western Blot

    Duolink Assay results for static and flow exposed HAEC. Protein associations determined by Cy3 channel confocal microscopy signal. Nuclei are counterstained with 4',6-diamidino-2-phenylindole (DAPI). A: total Akt and Smad2 association, n = 2. B: Smad2 and pAkt473 association. Enhanced cytoplasmic staining is evident with both sets of antibodies, indicating that colocalization of the proteins was occurring preferentially under flow stimulation.
    Figure Legend Snippet: Duolink Assay results for static and flow exposed HAEC. Protein associations determined by Cy3 channel confocal microscopy signal. Nuclei are counterstained with 4',6-diamidino-2-phenylindole (DAPI). A: total Akt and Smad2 association, n = 2. B: Smad2 and pAkt473 association. Enhanced cytoplasmic staining is evident with both sets of antibodies, indicating that colocalization of the proteins was occurring preferentially under flow stimulation.

    Techniques Used: Confocal Microscopy, Staining

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • pakt 473 smad2 raised  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc pakt 473 smad2 raised
    Smad protein levels for human aortic endothelial cells (HAEC) exposed to 20 h of 2 and 10 dyn/cm2 average shear stresses at 80 ± 5 mmHg and exemplary Western blot lanes. Each plot point represents the average value for the indicated number of samples. Western blot quantification was performed on raw image data and normalized to total kinase levels for each lane. A: cytosolic (n = 10) and nuclear (n = 3) L-psmad2 profiles. B: Western blot lanes showing COOH-terminal phosphorylated <t>Smad2</t> levels under flow for 20 h or treated with 1 ng/ml transforming growth factor (TGF)-β1 for 1 h. *P < 0.05.
    Pakt 473 Smad2 Raised, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pakt 473 smad2 raised/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pakt 473 smad2 raised - by Bioz Stars, 2023-03
    96/100 stars
    		  Buy from Supplier
    smad2 3 pakt  (Cell Signaling Technology Inc)
    86
    Cell Signaling Technology Inc smad2 3 pakt
    A., and <t>Smad2</t> and Smad3 mRNA B. ; and TMEPAI mRNA C. in human normal mammary epithelial cells (HMEC) and various triple negative breast cancer cell lines (MDA-MB-231, BT20, HCC1937, MDA-MB-157, Hs578T) along with TMEPAI knockdown MDA-MB-231 cells (231-TMKD/TMKD).
    Smad2 3 Pakt, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/smad2 3 pakt/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    smad2 3 pakt - by Bioz Stars, 2023-03
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Smad protein levels for human aortic endothelial cells (HAEC) exposed to 20 h of 2 and 10 dyn/cm2 average shear stresses at 80 ± 5 mmHg and exemplary Western blot lanes. Each plot point represents the average value for the indicated number of samples. Western blot quantification was performed on raw image data and normalized to total kinase levels for each lane. A: cytosolic (n = 10) and nuclear (n = 3) L-psmad2 profiles. B: Western blot lanes showing COOH-terminal phosphorylated Smad2 levels under flow for 20 h or treated with 1 ng/ml transforming growth factor (TGF)-β1 for 1 h. *P < 0.05.

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Flow-dependent Smad2 phosphorylation and TGIF nuclear localization in human aortic endothelial cells

    doi: 10.1152/ajpheart.00668.2010

    Figure Lengend Snippet: Smad protein levels for human aortic endothelial cells (HAEC) exposed to 20 h of 2 and 10 dyn/cm2 average shear stresses at 80 ± 5 mmHg and exemplary Western blot lanes. Each plot point represents the average value for the indicated number of samples. Western blot quantification was performed on raw image data and normalized to total kinase levels for each lane. A: cytosolic (n = 10) and nuclear (n = 3) L-psmad2 profiles. B: Western blot lanes showing COOH-terminal phosphorylated Smad2 levels under flow for 20 h or treated with 1 ng/ml transforming growth factor (TGF)-β1 for 1 h. *P < 0.05.

    Article Snippet: Primary antibodies to the targets of interest for each assay were used at the recommended immunofluorescence dilution (or 1:400 if no dilution given) and were from Cell Signaling Technology (pAKT 473 , Smad2 raised in rabbit, Akt) or Santa Cruz Biotechnology (Smad2 raised in mouse; Santa Cruz, CA).

    Techniques: Western Blot

    MAPK and Smad2 activity with chemical inhibitors of the ERK and phosphatidylinositol 3-kinase (PI3K) pathways at 20 h of 10 dyn/cm2, average shear stress at 80 ± 5 mmHg, and exemplary Western blot lanes. Plot points and blot quantification was performed as in Fig. 1. A: ERK phosphorylation in the presence of 10 μmol/l PD98059. For 10 dyn/cm2 and 10 dyn/cm2 + PD98059: n = 3. B: L-psmad2 levels in the presence of 10 μmol/l PD98059. For 10 dyn/cm2, n = 4, and for 10 dyn/cm2 + PD98059: n = 3. C: L-psmad2 levels in the presence of 40 μmol/l LY294002 and 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, for 10 dyn/cm2 + LY294002, n = 2, and for 10 dyn/cm2 + PI-103, n = 3. D: JNK phosphorylation in the presence of 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, and for 10 dyn/cm2 + PI-103, n = 3. *P < 0.05; **P < 0.01; ‡P < 0.0001.

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Flow-dependent Smad2 phosphorylation and TGIF nuclear localization in human aortic endothelial cells

    doi: 10.1152/ajpheart.00668.2010

    Figure Lengend Snippet: MAPK and Smad2 activity with chemical inhibitors of the ERK and phosphatidylinositol 3-kinase (PI3K) pathways at 20 h of 10 dyn/cm2, average shear stress at 80 ± 5 mmHg, and exemplary Western blot lanes. Plot points and blot quantification was performed as in Fig. 1. A: ERK phosphorylation in the presence of 10 μmol/l PD98059. For 10 dyn/cm2 and 10 dyn/cm2 + PD98059: n = 3. B: L-psmad2 levels in the presence of 10 μmol/l PD98059. For 10 dyn/cm2, n = 4, and for 10 dyn/cm2 + PD98059: n = 3. C: L-psmad2 levels in the presence of 40 μmol/l LY294002 and 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, for 10 dyn/cm2 + LY294002, n = 2, and for 10 dyn/cm2 + PI-103, n = 3. D: JNK phosphorylation in the presence of 1 μmol/l PI-103. For 10 dyn/cm2, n = 3, and for 10 dyn/cm2 + PI-103, n = 3. *P < 0.05; **P < 0.01; ‡P < 0.0001.

    Article Snippet: Primary antibodies to the targets of interest for each assay were used at the recommended immunofluorescence dilution (or 1:400 if no dilution given) and were from Cell Signaling Technology (pAKT 473 , Smad2 raised in rabbit, Akt) or Santa Cruz Biotechnology (Smad2 raised in mouse; Santa Cruz, CA).

    Techniques: Activity Assay, Western Blot

    Duolink Assay results for static and flow exposed HAEC. Protein associations determined by Cy3 channel confocal microscopy signal. Nuclei are counterstained with 4',6-diamidino-2-phenylindole (DAPI). A: total Akt and Smad2 association, n = 2. B: Smad2 and pAkt473 association. Enhanced cytoplasmic staining is evident with both sets of antibodies, indicating that colocalization of the proteins was occurring preferentially under flow stimulation.

    Journal: American Journal of Physiology - Heart and Circulatory Physiology

    Article Title: Flow-dependent Smad2 phosphorylation and TGIF nuclear localization in human aortic endothelial cells

    doi: 10.1152/ajpheart.00668.2010

    Figure Lengend Snippet: Duolink Assay results for static and flow exposed HAEC. Protein associations determined by Cy3 channel confocal microscopy signal. Nuclei are counterstained with 4',6-diamidino-2-phenylindole (DAPI). A: total Akt and Smad2 association, n = 2. B: Smad2 and pAkt473 association. Enhanced cytoplasmic staining is evident with both sets of antibodies, indicating that colocalization of the proteins was occurring preferentially under flow stimulation.

    Article Snippet: Primary antibodies to the targets of interest for each assay were used at the recommended immunofluorescence dilution (or 1:400 if no dilution given) and were from Cell Signaling Technology (pAKT 473 , Smad2 raised in rabbit, Akt) or Santa Cruz Biotechnology (Smad2 raised in mouse; Santa Cruz, CA).

    Techniques: Confocal Microscopy, Staining

    A., and Smad2 and Smad3 mRNA B. ; and TMEPAI mRNA C. in human normal mammary epithelial cells (HMEC) and various triple negative breast cancer cell lines (MDA-MB-231, BT20, HCC1937, MDA-MB-157, Hs578T) along with TMEPAI knockdown MDA-MB-231 cells (231-TMKD/TMKD).

    Journal: Genes & Cancer

    Article Title: Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

    doi: 10.18632/genesandcancer.194

    Figure Lengend Snippet: A., and Smad2 and Smad3 mRNA B. ; and TMEPAI mRNA C. in human normal mammary epithelial cells (HMEC) and various triple negative breast cancer cell lines (MDA-MB-231, BT20, HCC1937, MDA-MB-157, Hs578T) along with TMEPAI knockdown MDA-MB-231 cells (231-TMKD/TMKD).

    Article Snippet: Materials: TGF-β (R&D, MN), Antibodies to TMEPAI/PMEPA1 (Abnova, (mouse monoclonal) Taiwan and Proteintech, (rabbit polyclonal) CA), pSmad3 (Rockland, PA), H33258 (Bisbenzimide) and Tubulin (Sigma, MO), GAPDH (R&D, MN), pSmad2, Smad2/3 pAkt, Akt, PTEN, Snail, Slug, p27 and Actin (Cell Signaling, MA).

    Techniques:

    A. Relative levels of Smad2, Smad3, TMEPAI and GAPDH in MDA-MB-231 cells expressing control shRNA, Smad2 shRNA and Smad3 shRNA. B.-E. Growth curves of MDA-MB-231 cells expressing control shRNA (B), Smad2 shRNA (C), Smad3 shRNA (D) and TMEPAI shRNA (E) in the absence or presence of TGF-β (2 ng/ml).

    Journal: Genes & Cancer

    Article Title: Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

    doi: 10.18632/genesandcancer.194

    Figure Lengend Snippet: A. Relative levels of Smad2, Smad3, TMEPAI and GAPDH in MDA-MB-231 cells expressing control shRNA, Smad2 shRNA and Smad3 shRNA. B.-E. Growth curves of MDA-MB-231 cells expressing control shRNA (B), Smad2 shRNA (C), Smad3 shRNA (D) and TMEPAI shRNA (E) in the absence or presence of TGF-β (2 ng/ml).

    Article Snippet: Materials: TGF-β (R&D, MN), Antibodies to TMEPAI/PMEPA1 (Abnova, (mouse monoclonal) Taiwan and Proteintech, (rabbit polyclonal) CA), pSmad3 (Rockland, PA), H33258 (Bisbenzimide) and Tubulin (Sigma, MO), GAPDH (R&D, MN), pSmad2, Smad2/3 pAkt, Akt, PTEN, Snail, Slug, p27 and Actin (Cell Signaling, MA).

    Techniques: Expressing, shRNA

    A. Relative expression of phospho Smad2/3, Total Smad2/3 and TMEPAI in MDA-MB-231 cells expressing Con shRNA, Smad2 shRNA and Smad3 shRNA in the absence or presence of TGF-β (2 ng/ml), B. Relative levels of TMEPAI mRNAs in human mammary epithelial cells (HME) and MDA-MB-231 cells that are expressing Con shRNA, TMEPAI shRNA (TMKD), Smad2 shRNA (Smad2KD) or Smad3 shRNA (Smad3KD) in the absence or presence of TGF-β (2 ng/ml), C. 12XCAGA-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA, Smad2 shRNA, Smad3 shRNA both in the absence or presence of TGF-β (2 ng/ml). D. 3XARE-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA, Smad2 shRNA, Smad3 shRNA both in the absence or presence of TGF-β (2 ng/ml). E. 12xCAGA-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA (231_CON) and TMEPAI shRNA (231_TMKD) in the absence or presence of TGF-β (2 ng/ml). F. 3XARE-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA (231_CON) and TMEPAI shRNA (231_TMKD) in the absence or presence of TGF-β (2 ng/ml). G. Schematic representation of three different size TMEPAI promoters tagged with luciferase reporter (−2251-Luc, −973-Luc, −301-Luc) and corresponding luciferase reporter activities in MDA-MB-231 cells in the absence or presence of TGF-β (2 ng/ml). H. TMEPAI promoter activity in MDA-MB-231 cells expressing con shRNA, Smad2 shRNA, and Smad3 shRNA in the absence or presence of TGF-β (2 ng/ml) using 2251 bp TMEPAI promoter (−2251-Luc).

    Journal: Genes & Cancer

    Article Title: Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

    doi: 10.18632/genesandcancer.194

    Figure Lengend Snippet: A. Relative expression of phospho Smad2/3, Total Smad2/3 and TMEPAI in MDA-MB-231 cells expressing Con shRNA, Smad2 shRNA and Smad3 shRNA in the absence or presence of TGF-β (2 ng/ml), B. Relative levels of TMEPAI mRNAs in human mammary epithelial cells (HME) and MDA-MB-231 cells that are expressing Con shRNA, TMEPAI shRNA (TMKD), Smad2 shRNA (Smad2KD) or Smad3 shRNA (Smad3KD) in the absence or presence of TGF-β (2 ng/ml), C. 12XCAGA-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA, Smad2 shRNA, Smad3 shRNA both in the absence or presence of TGF-β (2 ng/ml). D. 3XARE-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA, Smad2 shRNA, Smad3 shRNA both in the absence or presence of TGF-β (2 ng/ml). E. 12xCAGA-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA (231_CON) and TMEPAI shRNA (231_TMKD) in the absence or presence of TGF-β (2 ng/ml). F. 3XARE-Luc reporter activity in MDA-MB-231 cells expressing Con ShRNA (231_CON) and TMEPAI shRNA (231_TMKD) in the absence or presence of TGF-β (2 ng/ml). G. Schematic representation of three different size TMEPAI promoters tagged with luciferase reporter (−2251-Luc, −973-Luc, −301-Luc) and corresponding luciferase reporter activities in MDA-MB-231 cells in the absence or presence of TGF-β (2 ng/ml). H. TMEPAI promoter activity in MDA-MB-231 cells expressing con shRNA, Smad2 shRNA, and Smad3 shRNA in the absence or presence of TGF-β (2 ng/ml) using 2251 bp TMEPAI promoter (−2251-Luc).

    Article Snippet: Materials: TGF-β (R&D, MN), Antibodies to TMEPAI/PMEPA1 (Abnova, (mouse monoclonal) Taiwan and Proteintech, (rabbit polyclonal) CA), pSmad3 (Rockland, PA), H33258 (Bisbenzimide) and Tubulin (Sigma, MO), GAPDH (R&D, MN), pSmad2, Smad2/3 pAkt, Akt, PTEN, Snail, Slug, p27 and Actin (Cell Signaling, MA).

    Techniques: Expressing, shRNA, Activity Assay, Luciferase

    A. Growth curves of MDA-MB-231 cells expressing control shRNA (CON shRNA), Smad2 shRNA, Smad3 shRNA or Smad3shRNA along with human TMEPAI cDNA (Smad3 shRNA+hTM) in the absence or presence of TGF-β (2 ng/ml). B. Relative expression of phosphorylated Akt (pAkt), Smad2, Smad3, Snail, Slug, PTEN, p27 and TMEPAI in MDA-MB-231 cells expressing Con shRNA (CON), Smad2 shRNA (S2KD), Smad3 shRNA (S3KD) and Smad3 shRNA along with human TMEPAI cDNA (S3KD+hTM) in the absence or presence of TGF-β (2 ng/ml). Phase contrast images of toluidine blue stained transit well invasion assay (C) and relative invasion index (D) of MDA-MB-231 cells expressing control shRNA (CON shRNA), Smad2 shRNA, Smad3 shRNA and Smad3shRNA along with human TMEPAI cDNA in the absence or presence of TGF-β (2 ng/ml).

    Journal: Genes & Cancer

    Article Title: Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

    doi: 10.18632/genesandcancer.194

    Figure Lengend Snippet: A. Growth curves of MDA-MB-231 cells expressing control shRNA (CON shRNA), Smad2 shRNA, Smad3 shRNA or Smad3shRNA along with human TMEPAI cDNA (Smad3 shRNA+hTM) in the absence or presence of TGF-β (2 ng/ml). B. Relative expression of phosphorylated Akt (pAkt), Smad2, Smad3, Snail, Slug, PTEN, p27 and TMEPAI in MDA-MB-231 cells expressing Con shRNA (CON), Smad2 shRNA (S2KD), Smad3 shRNA (S3KD) and Smad3 shRNA along with human TMEPAI cDNA (S3KD+hTM) in the absence or presence of TGF-β (2 ng/ml). Phase contrast images of toluidine blue stained transit well invasion assay (C) and relative invasion index (D) of MDA-MB-231 cells expressing control shRNA (CON shRNA), Smad2 shRNA, Smad3 shRNA and Smad3shRNA along with human TMEPAI cDNA in the absence or presence of TGF-β (2 ng/ml).

    Article Snippet: Materials: TGF-β (R&D, MN), Antibodies to TMEPAI/PMEPA1 (Abnova, (mouse monoclonal) Taiwan and Proteintech, (rabbit polyclonal) CA), pSmad3 (Rockland, PA), H33258 (Bisbenzimide) and Tubulin (Sigma, MO), GAPDH (R&D, MN), pSmad2, Smad2/3 pAkt, Akt, PTEN, Snail, Slug, p27 and Actin (Cell Signaling, MA).

    Techniques: Expressing, shRNA, Staining, Invasion Assay

    Relative mRNA expression of Smad2 A. , Smad3 B. , TMEPAI C. , Snai1 D. , Slug E. in MDA-MB-231 (231) cells that are expressing control, TMEPAI (TMKD), Smad2 (Smad2KD) and Smad3 (Smad3KD) shRNAs in the absence or presence of TGF-β (2 ng/ml) relative to normal human mammary epithelial cells (HMEC).

    Journal: Genes & Cancer

    Article Title: Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

    doi: 10.18632/genesandcancer.194

    Figure Lengend Snippet: Relative mRNA expression of Smad2 A. , Smad3 B. , TMEPAI C. , Snai1 D. , Slug E. in MDA-MB-231 (231) cells that are expressing control, TMEPAI (TMKD), Smad2 (Smad2KD) and Smad3 (Smad3KD) shRNAs in the absence or presence of TGF-β (2 ng/ml) relative to normal human mammary epithelial cells (HMEC).

    Article Snippet: Materials: TGF-β (R&D, MN), Antibodies to TMEPAI/PMEPA1 (Abnova, (mouse monoclonal) Taiwan and Proteintech, (rabbit polyclonal) CA), pSmad3 (Rockland, PA), H33258 (Bisbenzimide) and Tubulin (Sigma, MO), GAPDH (R&D, MN), pSmad2, Smad2/3 pAkt, Akt, PTEN, Snail, Slug, p27 and Actin (Cell Signaling, MA).

    Techniques: Expressing

    A. Relative expression of Smad2, Smad3 and TMEPAI in Control (HCC), Smad2 knockdown (S2KD) and Smad3 knockdown (S3KD) HCC1937 TNBC cells. B. Growth of control HCC1937 (HCC) in the presence and absence of TGF-β. C. Growth of Smad2 knockdown HCC1937 (S2KD) in the presence and absence of TGF-β. D. Growth of Smad3 knockdown HCC1937 (S3KD) in the presence and absence of TGF-β. E. Relative expressions of E-Cad, Snail and Slug in control (CON) and TMEPAI knockdown (TMKD) HCC1937 cells. F. Relative expressions of E-Cad and Vimentin in control (CON), Smad2 knockdown (S2KD) and Smad3 knockdown (S3KD) HCC1937 cells.

    Journal: Genes & Cancer

    Article Title: Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

    doi: 10.18632/genesandcancer.194

    Figure Lengend Snippet: A. Relative expression of Smad2, Smad3 and TMEPAI in Control (HCC), Smad2 knockdown (S2KD) and Smad3 knockdown (S3KD) HCC1937 TNBC cells. B. Growth of control HCC1937 (HCC) in the presence and absence of TGF-β. C. Growth of Smad2 knockdown HCC1937 (S2KD) in the presence and absence of TGF-β. D. Growth of Smad3 knockdown HCC1937 (S3KD) in the presence and absence of TGF-β. E. Relative expressions of E-Cad, Snail and Slug in control (CON) and TMEPAI knockdown (TMKD) HCC1937 cells. F. Relative expressions of E-Cad and Vimentin in control (CON), Smad2 knockdown (S2KD) and Smad3 knockdown (S3KD) HCC1937 cells.

    Article Snippet: Materials: TGF-β (R&D, MN), Antibodies to TMEPAI/PMEPA1 (Abnova, (mouse monoclonal) Taiwan and Proteintech, (rabbit polyclonal) CA), pSmad3 (Rockland, PA), H33258 (Bisbenzimide) and Tubulin (Sigma, MO), GAPDH (R&D, MN), pSmad2, Smad2/3 pAkt, Akt, PTEN, Snail, Slug, p27 and Actin (Cell Signaling, MA).

    Techniques: Expressing

    Kaplan Meier curves for overall survival of triple negative breast cancer patients in relation to expression of TMEPAI/PMEPA1 (A), Smad2 (B), Smad3 (C) or Smad4 (D) mRNA using a publicly accessible database (GSE58812). E. Western blots of TMEPAI and total Smad2/3 proteins in primary tumors from human breast cancer patients (BC1- BC5) and corresponding normal/benign (N1-N4) samples relative to MDA-MB-231 cells (231).

    Journal: Genes & Cancer

    Article Title: Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

    doi: 10.18632/genesandcancer.194

    Figure Lengend Snippet: Kaplan Meier curves for overall survival of triple negative breast cancer patients in relation to expression of TMEPAI/PMEPA1 (A), Smad2 (B), Smad3 (C) or Smad4 (D) mRNA using a publicly accessible database (GSE58812). E. Western blots of TMEPAI and total Smad2/3 proteins in primary tumors from human breast cancer patients (BC1- BC5) and corresponding normal/benign (N1-N4) samples relative to MDA-MB-231 cells (231).

    Article Snippet: Materials: TGF-β (R&D, MN), Antibodies to TMEPAI/PMEPA1 (Abnova, (mouse monoclonal) Taiwan and Proteintech, (rabbit polyclonal) CA), pSmad3 (Rockland, PA), H33258 (Bisbenzimide) and Tubulin (Sigma, MO), GAPDH (R&D, MN), pSmad2, Smad2/3 pAkt, Akt, PTEN, Snail, Slug, p27 and Actin (Cell Signaling, MA).

    Techniques: Expressing, Western Blot

    The data demonstrate that the consequences of switch from Smad2 to Smad3 signaling pathway results in converting TGF-β from tumor suppressor to pro-oncogene as cells acquire increasing malignant properties through Smad3 mediated TMEPAI expression.

    Journal: Genes & Cancer

    Article Title: Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

    doi: 10.18632/genesandcancer.194

    Figure Lengend Snippet: The data demonstrate that the consequences of switch from Smad2 to Smad3 signaling pathway results in converting TGF-β from tumor suppressor to pro-oncogene as cells acquire increasing malignant properties through Smad3 mediated TMEPAI expression.

    Article Snippet: Materials: TGF-β (R&D, MN), Antibodies to TMEPAI/PMEPA1 (Abnova, (mouse monoclonal) Taiwan and Proteintech, (rabbit polyclonal) CA), pSmad3 (Rockland, PA), H33258 (Bisbenzimide) and Tubulin (Sigma, MO), GAPDH (R&D, MN), pSmad2, Smad2/3 pAkt, Akt, PTEN, Snail, Slug, p27 and Actin (Cell Signaling, MA).

    Techniques: Expressing